TRDA vs WVE
TRDA: Entrada is a clinical-stage biotech advancing exon-skipping genetic medicines with proprietary endosomal escape technology to treat neuromuscular diseases like DMD, with multiple programs in Phase 1/2 trials and an partnership with Vertex on a DM1 therapy. WVE: A clinical-stage biotechnology company developing a versatile, multimodal RNA medicine platform to treat rare and common diseases without the need for complex delivery vehicles like lipid nanoparticles.
Side-by-side fundamentals
| Metric | TRDA | WVE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.15 | $5.74 | |
| Market cap as of 2026-07-23 | $239M | $1.1B | |
| PEG as of 2026-07-23 | n/a | -0.11 | |
| Net margin as of 2026-07-23 | -2895.1% | -255.7% | WVE higher |
| Operating margin as of 2026-07-23 | -3109.3% | -274.2% | WVE higher |
| ROE as of 2026-07-23 | -51.2% | -55.7% | TRDA higher |
| ROA as of 2026-07-23 | -42.2% | -42.8% | TRDA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | -96.7% | -31.6% | WVE higher |
| Revenue CAGR (3y) SEC XBRL | -55.6% | +127.1% | WVE higher |
| Beta as of 2026-07-23 | -0.28 | -1.33 | |
| 1-year return as of 2026-07-22 close | +5.2% | -27.6% | TRDA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.